Clinical Trial Update: Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating fludarabine, cyclophosphamide, and rituximab in patients with prolymphocytic leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prolymphocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Rituximab (rituximab)

Snippet

Sponsor: German CLL Study Group | Conditions: Prolymphocytic Leukemia | Phase 2 | Status: TERMINATED